Greenphire, a leading innovator in software solutions for streamlining clinical trials, has announced the acquisition of Clincierge, a premier provider of concierge travel and logistics support for patients participating in clinical trials. The deal aims to revolutionize the landscape of trial support services by integrating unparalleled patient care with cutting-edge technology.

The acquisition will enhance the participant journey and simplify trial processes for pharmaceutical companies and clinical research organizations worldwide. Greenphire and Clincierge will offer a comprehensive, end-to-end participant experience platform that includes reimbursement, travel, mobile technology, and high-touch support. The acquisition will also prioritize patient-centric care, improve patient engagement and satisfaction, streamline trial operations, and drive innovation and growth within the trial support industry.

Greenphire CEO, Jim Murphy, said, “This acquisition marks a significant milestone for Greenphire as we reinforce our commitment to transforming the landscape of trial support services. By combining our technological prowess with Clincierge’s dedication to exceptional patient care, we are poised to redefine industry standards and drive meaningful advancements in clinical research.”

Clincierge CEO, Scott Gray, said, “Joining forces with Greenphire presents an exciting opportunity to elevate our patient-centered services. Together, we will revolutionize how patients experience clinical trials, offering unparalleled support and empowering them to participate in trials with greater ease and comfort.”

The acquisition reflects the industry’s demand for improving travel and logistical support for trial participants, as indicated by Greenphire’s 2023 Participant Convenience Market Research Survey. The acquisition also underscores Greenphire’s dedication to being the premier partner for the industry to advance the efficiency, accessibility, and quality of clinical trials globally. Both companies are excited about the opportunities this collaboration will bring and look forward to delivering enhanced value to pharmaceutical partners and patients alike.

The transaction was advised by Morris, Manning & Martin, Stradley Ronon Stevens & Young, and Bourne Partners.